N/A
Manufactured by McKesson
326 FDA adverse event reports analyzed
Last updated: 2026-04-15
BENZETHONIUM CHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by McKesson. The most commonly reported adverse reactions for BENZETHONIUM CHLORIDE include NAUSEA, HYPERSENSITIVITY, HEADACHE, THERAPEUTIC PRODUCT EFFECT DECREASED, CONTRAINDICATED PRODUCT ADMINISTERED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BENZETHONIUM CHLORIDE.
Out of 124 classified reports for BENZETHONIUM CHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 326 FDA FAERS reports that mention BENZETHONIUM CHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include NAUSEA, HYPERSENSITIVITY, HEADACHE, THERAPEUTIC PRODUCT EFFECT DECREASED, CONTRAINDICATED PRODUCT ADMINISTERED, APPLICATION SITE PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list McKesson in connection with BENZETHONIUM CHLORIDE. Always verify the specific product and NDC with your pharmacist.